Annual General Meeting of Active Biotech AB
May 27 2016 - 1:30AM
The Annual General Meeting of Active Biotech was
held on May 26, 2016.
In accordance with the Board of Directors'
proposal, it was resolved that no dividend would be paid.
The board members and the managing director were
discharged from liability with respect to their management of the
company for 2015.
In accordance with the Election
Committee's proposal, the Board members Mats Arnhög, Magnhild
Sandberg-Wollheim, Peter Sjöstrand and Peter Thelin were
re-elected. The Meeting also resolved to re-elect Mats Arnhög as
Chairman of the Board. KPMG AB was re-elected as auditor.
Furthermore, in accordance with the Election
Committee's proposal, the Meeting resolved that the Election
Committee shall be composed of representatives for the three
largest owners, as per the end of September, 2016, as well as the
Chairman of the Board.
The Meeting approved the Board's proposal
concerning guidelines for remuneration to the President and other
senior executives. The guidelines conform to the principles applied
to date.
In accordance with the Board's proposal, the
Meeting resolved to authorize the Board, for a period that does not
extend past the date of the next Annual General Meeting, to resolve
on the issue of not more than seven million new shares and/or
convertibles with the corresponding dilution effect, with or
without pre-emptive rights for the company's shareholders.
Lund, May 27, 2016
Active Biotech AB (publ)
Tomas Leanderson
President and CEO
For further information, please
contact:
Hans Kolam, CFO
Tel +46 46 19 20 44
Active Biotech AB
(publ) (Nasdaq Stockholm: ACTI) is a biotechnology company with
focus on neurodegenerative/inflammatory diseases and cancer.
Laquinimod, an orally administered small molecule with unique
immunomodulatory properties, is in pivotal Phase 3 development for
the treatment of relapsing remitting multiple sclerosis. Also,
laquinimod is in Phase 2 development for the treatment of primary
progressive multiple sclerosis and Huntington's disease.
Furthermore, commercial activities are conducted for the
tasquinimod, SILC, ANYARA and paquinimod projects. Please visit
www.activebiotech.com for more information.
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
Active Biotech is obligated to
publish the information contained in this press release in
accordance with the Swedish Securities Market Act and/or
the Financial Instruments Trading Act. This information was provided to the media for
publication at 8:30 a.m. CET on May 27,
2016.
160527_Årsstämma_2016_Eng
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
HUG#2015738
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2024 to May 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From May 2023 to May 2024